Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S
Condition: MERS (Middle East Respiratory Syndrome) Intervention: Biological: vaccine candidate MVA-MERS-S Sponsors: Marylyn Addo; Philipps University Marburg Medical Center; Ludwig-Maximilians - University of Munich; Charite University, Berlin, Germany; Bernhard Nocht Institute for Tropical Medicine; University of Cologne Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 6, 2018 Category: Research Source Type: clinical trials
Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon- β1b (MIRACLE trial): study protocol for a randomized controlled trial
DiscussionThis will be the first randomized controlled trial of a potential treatment for MERS. The study is sponsored by King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. Enrollment for this study began in November 2016, and has enrolled thirteen patients as of Jan 24-2018.Trial registrationClinicalTrials.gov, ID:NCT02845843. Registered on 27 July 2016. (Source: Trials)
Source: Trials - January 30, 2018 Category: Research Source Type: clinical trials
Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)
Condition: MERS (Middle East Respiratory Syndrome) Intervention: Biological: ChAdOx1 MERS Sponsor: University of Oxford Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2018 Category: Research Source Type: clinical trials
